Background/aims: The Lewis Score (LS) can assess inflammatory activity on small bowel capsule endoscopy (SBCE). We aimed to evaluate the LS usefulness in the setting of suspected Crohn's Disease (CD). Methods: Retrospective single-center study including 56 patients undergoing SBCE for suspected CD. Patients were divided into three groups, according to clinical presentation: Group 1 (28 patients): suspected CD not supported by the International Conference on Capsule Endoscopy (ICCE) criteria; Group 2 (19 patients): suspected CD based on two ICCE criteria; Group 3 (9 patients): patients fulfilling three or more criteria. Inflammatory activity was assessed with the LS. The diagnosis of CD required a minimum follow-up of 6 months after SBCE, basing on clinical evaluation, endoscopic, histological, radiological, and/or biochemical investigations. Results: SBCE detected significant inflammatory activity (LS ≥ 135) in 23 patients (41.1%), being 5 patients from Group 1 (17.8%), 11 from Group 2 (57.9%) and 7 from Group 3 (77.8%) (p b 0.05). CD was diagnosed in 23 patients (41.1%): six patients from Group 1 (21.4%), 10 from Group 2 (52.6%) and 7 from Group 3 (77.8%) (p b 0.05). CD was diagnosed in 82.6% of patients with significant inflammatory activity on CE (LS ≥ 135), but in only 12.1% of those having a LS b 135 (p b 0.05). The LS Positive Predictive Value, Negative Predictive Value, Sensitivity and Specificity were 82.6%, 87.9%, 82.6% and 87.9%, respectively. Conclusions: The LS may be a valuable diagnostic tool in the setting of suspected CD. Patients not fulfilling the ICCE criteria have lower LS and fewer are diagnosed with CD during follow-up.
Introduction
Small bowel capsule endoscopy (SBCE) is currently the most sensitive diagnostic technique to noninvasively detect early small bowel mucosal disease. [1] [2] [3] One of the widely accepted indications for SBCE is the setting of suspected Crohn's Disease (CD). However, the lack of specificity of endoscopic findings, suboptimal interobserver agreement and lack of tissue sampling may increase the risk of inaccurate diagnoses. The Lewis Score (LS), 4 which has been integrated into the latest software from the PillCam® (Given®, RAPID Reader®), has been developed with the purpose of increasing the objectivity and maximizing interobserver agreement, when assessing SBCE inflammatory activity. It uses a standard terminology for the description of endoscopic lesions, the capsule endoscopy structured terminology (CEST), [5] [6] and grades the inflammatory activity through a rank of severity, with the premise that the final numerical score reflects the physician's global assessment of disease.
In this study, we aimed to evaluate if the assessment and grading of the severity of inflammation on SBCE with the LS may be useful as a diagnostic tool for patients with suspected CD.
Materials and methods
We conducted a retrospective single-center study, including fifty-six consecutive patients (61% female, mean age 36 ± 14.7 years ) with suspected CD submitted to SBCE. Exclusion criteria were medication with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) in the last month, presence of endoscopic inflammatory lesions in the colonoscopy and/or upper endoscopy, patients with obstructive symptoms in the last 6 months, and patients with less than 6 months of follow-up after CE.
The International Conference on Capsule Endoscopy (ICCE) recommended that patients with suspected CD presenting with suggestive symptoms (A) plus either extraintestinal manifestations (B), inflammatory markers (C), or abnormal imaging studies (D) should be selected to undergo SBCE 7 - Fig. 1 . Based on this algorithm, we defined three groups of patients, according to their clinical presentation: Group 1 -patients that did not fulfill the ICCE criteria; Group 2 -patients with suspected CD based on conjugation of two criteria; and Group 3 -patients with three or more criteria, thus having the highest pretest probability of CD. Twenty-eight patients were included in Group 1 (50%), 19 in Group 2 (34%) and 9 in Group 3 (16%). All patients had been submitted to colonoscopy prior to SBCE, with retrograde ileoscopy being performed on 47 patients (83.9%). Forty-one patients (73.2%) were submitted to upper endoscopy prior to SBCE. Twenty-six patients (46.4%) had been submitted to small bowel imaging with small bowel followthrough or computerized tomography (CT) scan; nine of those patients (34.6%) had radiological features suggestive of CD, although no evidence of stricturing lesions. Patients' demographics, as well as clinical characteristics (ICCE criteria) and endoscopic, imaging features previous to SBCE are summarized in Table 1 .
All patients followed a clear liquid diet for 24 h plus 12 h fasting prior to CE (PillCam® SB, Given® Imaging Ltd. Yoqneam, Israel). No oral purge was administered. We used RAPID Reader® 5 to review CE images, and systematically assessed inflammatory activity for each patient with determination of the respective LS, using the automatic calculator included in the RAPID® software. The LS allowed the ranking of inflammatory activity into three levels: 1) no disease or clinically insignificant disease (LS b 135); 2) mild disease (135 ≤ LS ≤ 790); and 3) moderate or severe disease (LS N 790). 4 The diagnosis of CD during the follow-up period (minimum six months) was established basing on a combination of clinical evaluation, endoscopic, histological, radiological, and/ or biochemical investigations.
Statistical analyses were performed using SPSS version 16.0 (SPSS Inc., Chicago, Illinois). Comparisons of categorical data were performed using the chi-squared test. For numeric variables we used one-way analysis of variance (ANOVA).
Results
Patients were followed-up for a mean period of 21.2 ± 12.9 months .
Twenty-six patients (46.4%) underwent small bowel imaging previous to SBCE, either with small bowel follow-through or CT scan. Nine of those patients (34.6%) had some radiologic Figure 1 ICCE criteria for suspected Crohn's Disease. was detected in 5 (17.8%), 11 (57.9%) and 7 (77.8%) patients (p b 0.05), and it was moderate or severe (LS N 790) in 1 (3.6%), 3 (15.8%) and 3 (33.3%), respectively (p = 0.55). Overall, significant inflammatory activity was detected in 23 patients (41.1%), and CD was confirmed during the follow-up in 19 of those patients (Positive Predictive Value, PPV = 82.6%). On the other hand, in 33 patients (58.9%), SBCE revealed no disease or clinically insignificant disease (LS b 135), and in 29 of those patients, the diagnosis of CD was excluded during the follow-up (Negative Predictive Value, NPV = 87.9%). SBCE had identified significant inflammatory activity (LS ≥ 135) in 19 of the 23 patients who were diagnosed with CD during follow-up (Sensitivity = 82.6%). Conversely, it revealed no disease or clinically insignificant disease (LS b 135) in 29 of the 33 patients who were not diagnosed with CD during the follow-up period (Specificity = 87.9%) - Table 2 .
The diagnosis of CD was established in 82.6% of the patients with significant inflammatory activity on SBCE (LS ≥ 135), but in only 12.1% of those who had a LS b 135 (p b 0.05). Overall, the diagnosis of CD was established during follow-up in 23 patients (41.1%), being 6 patients from Group 1 (21.4%), 10 patients from Group 2 (52.6%) and 7 patients from Group 3 (77.8%) (p b 0.05). In 13 of those patients (56.5%), the diagnosis was histologically confirmed during the follow-up (6 patients underwent colonoscopy with retrograde ileoscopy and biopsies from the terminal ileum, 4 patients underwent single-balloon enteroscopy and 3 patients were submitted to surgery), while in the other 10 patients (43.5%) the diagnosis was established by the referring physician during the follow-up, based on a combination of clinical evaluation, response to therapy, as well as additional imaging and/or biochemical data - Table 2 . If a positive histology had been required to firm the diagnosis of CD during follow-up, 13 patients would have met that criterion, being 5 patients from Group 1 (17.9%), 3 patients from Group 2 (15.8%) and 5 patients from Group 3 (55.6%) (p b 0.05). SBCE features would be different in this setting, with higher Sensitivity and NPV, and lower Specificity and PPV, as follows: Sensitivity = 84.6% (11 patients with LS ≥ 135 among those 13 patients with histologically confirmed CD during follow-up); NPV = 93.4% (31 patients without histological confirmation of CD out of 33 with LS b 135); Specificity = 72.1% (31 patients with LS b 135 out of the 43 patients in which CD was not histologically confirmed); and PPV = 47.8% (11 patients with histologically confirmed CD out of 23 with LS ≥ 135).
Overall, SBCE transit time was 287.6 ± 101.2 min [54-525], with no significant differences between groups. In our series, the capsule did not reach the cecum within the battery lifespan in 9 patients (16.1%); this proportion was significantly different between groups (3.6% in Group 1 versus 15.8% in Group 2 and 55.6% in Group 3, p b 0.05). Capsule retention occurred in four patients (7.1%) -2 patients in Group 2 and 2 patients in Group 3 - Table 2 .
The Table 3 summarizes the demographic and clinical characteristics of the 23 patients with confirmed CD during the follow-up.
Discussion
Up to 33% of CD patients have small bowel disease out of the reach of standard endoscopy, making the diagnosis more challenging. In this setting, SBCE may contribute to an earlier diagnosis of CD, or otherwise play a key role at excluding the diagnosis when no significant lesions are found. Indeed, a recently published OMED-ECCO consensus stated that SBCE may identify lesions compatible with CD in some patients in whom conventional endoscopic and radiographic imaging modalities have been nondiagnostic, and that a normal SBCE has a high negative predictive value for active small bowel CD. [10] [11] [12] However, the lack of specificity of SBCE endoscopic findings, suboptimal interobserver agreement and lack of tissue sampling may increase the risk of inaccurate diagnoses, highlighting the importance of adopting a common language to describe endoscopic lesions, as well as uniform criteria to grade and classify the severity of the inflammation. Several indices have been developed in an effort to distinguish significant endoscopic findings from the innocent lesions found in the general population; while neither system has gained general acceptance, the LS has been integrated into the latest software from the PillCam® (Given®, RAPID Reader®), making it more accessible. 4 This scoring system has been refined to quantify mucosal damage based on villous appearance (edema), ulcer, and stenosis, while minor mucosal breaks, erythema, nodularity or villous atrophy are not scored, because of their lower clinical relevance or lower interobserver agreement - Fig. 2 . A score b 135 corresponds to normal or clinically insignificant mucosal inflammatory change, a score between 135 and 790 is mild disease, and a score ≥ 790 corresponds to moderate or severe disease. When compared to the study by Mow et al., 13 which considered the presence of more than three ulcers to presume a diagnosis of CD, or one other study by Voderholzer et al., 14 where it was the detection of more than ten aphthoid or erosive lesions, the LS may theoretically increase the diagnostic yield of SBCE, as it includes patients with villous edema and/or stenosis with no associated mucosal ulceration. However, a caveat must be remarked: although the LS can quantitatively assess the number and severity of mucosal damage, it grades inflammation despite of its etiology, which means that it cannot distinguish among different diagnostic entities, and thus it must be interpreted with caution in each individual patient.
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This study shows that the diagnosis of CD was established much more frequently in patients with significant inflammatory activity on SBCE (LS ≥ 135). In our opinion, the routine use of the LS to characterize and grade small bowel inflammatory activity, when interpreted in the right clinical context, may be of great value in the setting of suspected CD, to assist clinicians in the interpretation of SBCE lesions and to guide decisions towards a more early and accurate diagnosis.
Similarly to other studies reported in the literature, 15 our study is limited to the fact that there is no gold standard for the diagnosis of small bowel CD. The diagnosis of CD was assessed during the follow-up with a combination of clinical evaluation, endoscopic, histological, radiological, and/or biochemical investigations. In almost half of the patients (43.5%, n = 10), the diagnosis was assumed by the referring physician without histological confirmation, based on a combination of clinical evaluation, response to therapy, as well as additional imaging and/or biochemical data during the period of follow-up. We think that this embracing and comprehensive follow-up is of paramount importance, as there is actually no single gold standard for the diagnosis of CD; as a matter of fact, it is interesting to remark that if we had considered only the 13 patients with histological confirmation during follow-up, CD would only have been assumed in 5 patients from Group 1 (17.9%) instead of 6 (21.4%), 3 A limitation of our study is represented by its retrospective design, and the fact that the characteristics of the study population were somewhat heterogeneous. As patients were divided into three groups according to clinical presentation, the number of patients in each subgroup was relatively small, and the number of patients was not equally distributed among groups, as the majority of those patients (50%) referred to Group 1. Nevertheless, this study design allowed us to evaluate, for each group individually, the rate of significant small bowel inflammatory activity on SBCE and its influence on subsequent management, highlighting the paramount importance of a careful selection of suspected CD patients to be submitted to SBCE. As a matter of fact, while the concept of suspected CD is still a matter of debate, with implications in the selection of the patients, the recognition that isolated abdominal pain or diarrhea should not constitute an indication for CE is being increasingly recognized. [16] [17] As our study included patients that did not fulfill the ICCE criteria (Group 1), it allowed us to conclude that those patients had the lowest rate of significant small bowel inflammatory activity, with lower LS, and lower percentage of patients being diagnosed with CD during follow-up.
In our series, ileoscopy was not performed prior to SBCE in 9 patients (16.1%). The fact that during follow-up the diagnosis of CD was confirmed based on ileoscopy in 6 patients (26% of patients with CD), highlights the importance of performing routine retrograde ileoscopy during colonoscopy in the setting of suspected CD. We also emphasize that, in our study, the diagnosis of CD was established in 16 patients out of the 47 who had a prior negative ileoscopy (34%), and SBCE showed significant inflammatory activity in 13 of those patients. In fact, other studies had previously shown that in a high percentage of patients, ileal involvement in CD may be outside the range of the ileoscopy, focusing the importance of SBCE in this setting. 18 The rate of incomplete enteroscopies was 16.1%, similar to the rates reported in other studies considering all indications. [19] [20] This proportion was significantly higher in patients selected according to the ICCE criteria (3.6% in Group 1 versus 15.8% in Group 2 and 55.6% in Group 3), the retention rate for diagnosed CD being 3/23 (13.0%). In most of the cases, this probably occurred due to a delay of capsule progression next to segments with inflammatory activity, such as edema or inflammatory stenoses. Two of those patients spontaneously passed the capsule within a few weeks, while in the other patient the capsule had to be surgically retrieved, due to obstructive symptoms and unsuccessful endoscopic retrieval with antegrade singleballoon enteroscopy. Overall, the capsule retention rate was higher (7%) when compared to other studies in the literature describing retention rates around 1.4% in the setting of suspected CD. 8, 21 Although there are currently no firm recommendations to perform imaging small bowel studies and/or patency capsule in the feature of suspected CD, all of the patients in our series who happened to retain the capsule had been previously submitted to imaging studies who did not suggest the presence of any stenosis. This conforms to other studies which demonstrate the low reliability of clinical and imaging studies in predicting the existence of stenoses. [21] [22] [23] In our institution, we do not have available Agile® patency system, which may be a useful tool to use before CE in patients at risk for capsule retention. 24 To summarize, it is our strong belief that this study supports the routine use of the LS to characterize and grade the small bowel inflammatory activity on SBCE. When interpreted in adequate clinical context, it may be of great value in the setting of suspected CD.
